What Mammoth Biosciences does

Mammoth Biosciences is a private biotechnology company founded in 2017–2018 by Jennifer Doudna (2020 Nobel laureate and CRISPR co-inventor), Trevor Martin, Janice Chen, and Lucas Harrington, headquartered in Brisbane, California. The company develops CRISPR-based platforms across two business lines: (1) in vivo gene editing therapeutics built on proprietary ultracompact nucleases (NanoCas and CasPhi) whose small size enables single-AAV and LNP delivery to extrahepatic tissues such as muscle and CNS, complemented by alternative editing modalities (base editing, epigenetic editing, RT editing) for precision and non-cutting gene modulation; and (2) the DETECTR molecular diagnostics platform, which uses CRISPR nucleases to detect disease-associated nucleic acids with results in 30–60 minutes.

The lead therapeutic program, MB-111, targets APOC3 knockout in the liver for Familial Chylomicronemia Syndrome and severe hypertriglyceridemia, and was nominated as Mammoth's first development candidate in April 2025. Underlying the portfolio is an AI-enabled protein discovery engine that screens one of the largest metagenomic databases and pairs in-silico prediction with high-throughput wet-lab screening to continuously generate new Cas systems.

Mammoth is pre-revenue commercially and monetizes almost exclusively through B2B partnership economics — upfront payments, development/regulatory/commercial milestones, and tiered royalties — rather than direct product sales. Anchor partnerships include Regeneron (2024: $100M upfront, up to $370M per target), Vertex (2021: $40M upfront, up to $650M potential), and Bayer (2022: $40M upfront for liver disease). The company has raised over $465M across venture rounds, achieving unicorn status in September 2021, and has a stated global footprint expanding into the Middle East via an MOU with Abu Dhabi's M42 and Department of Health in 2026. Customer segments are concentrated in major pharmaceutical and biotechnology partners, with secondary exposure to diagnostic companies and academic research institutions.

Name

Mammoth Biosciences

Legal name

Mammoth Biosciences, Inc.

Website

https://mammoth.bio

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Mammoth Biosciences is a private CRISPR biotechnology company that develops ultracompact nucleases (NanoCas, CasPhi) and the DETECTR diagnostics platform for in vivo gene editing and molecular detection, monetizing through strategic co-development and licensing partnerships with major pharmaceutical and biotechnology companies.

Ownership category

akta.pro rank

Product category

CRISPR Gene Editing Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• CRISPR gene editing
• In vivo therapeutics
• Molecular diagnostics
• Genetic medicine
• Genome engineering

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Strategic Partnerships and Licensing: Major revenue stream through strategic co-development partnerships with pharmaceutical companies. Mammoth provides access to its CRISPR editing technologies and receives upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales. Key deals include Regeneron ($100M upfront + up to $370M per target) and Vertex ($40M upfront + up to $650M total potential).
2. Diagnostic Platform Licensing: DETECTR platform technology available for licensing to diagnostic companies. Partnership with Hamilton Company and MilliporeSigma for commercialization of CRISPR-based SARS-CoV-2 testing.
3. Therapeutic Development: Development of proprietary therapeutic candidates through clinical stages with goal of commercializing gene editing therapies. Lead program MB-111 targeting triglycerides via APOC3 gene knockdown.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Mammoth Biosciences develops proprietary CRISPR-Cas gene editing platforms (NanoCas, CasPhi) and editing modalities (base editing, epigenetic editing, RT editing) to enable in vivo gene editing therapies for rare and inherited diseases. The company also offers the DETECTR® molecular diagnostics platform for CRISPR-based detection of nucleic acids indicative of disease.

Product overview

Mammoth Biosciences offers a CRISPR-based technology platform consisting of multiple integrated products. The core offering is the DETECTR® Platform for molecular diagnostics, which leverages CRISPR nucleases to detect specific nucleic acids for disease identification. For therapeutics, the company provides ultracompact CRISPR systems (NanoCas and CasPhi) along with novel editing modalities including Base Editing, Epigenetic Editing, and RT Editing platforms, all designed for in vivo gene therapy applications. These therapeutic components are uniquely compatible with single AAV and LNP delivery, enabling targeting of tissues beyond the liver. The lead therapeutic candidate MB-111 is advancing through development for triglyceride reduction.

Differentiator

Problem solved

Functional benefit

Brands

• DETECTR: CRISPR-based detection platform for molecular diagnostics that enables rapid detection of specific nucleic acids indicative of disease.

Products and services

• DETECTR® Platform

Quantifiable outcome

• MB-111 demonstrated robust triglyceride reduction in mouse models and non-human primates targeting APOC3 gene for FCS and sHTG treatment
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• M42coreStrategic or Co-development Partner · 25 June 2026Abu Dhabi's health company M42 partnered with Mammoth and Abu Dhabi Department of Health at BIO International Convention 2026 to develop CRISPR gene-editing therapies for rare and inherited diseases. Plans include introducing MB-111 into Abu Dhabi's clinical research ecosystem, establishing advanced therapy manufacturing capabilities including LNP production, and developing local gene-editing expertise.
• Abu Dhabi Department of HealthcoreStrategic or Co-development Partner · 25 June 2026Partnership with M42 and Mammoth Biosciences to develop CRISPR gene-editing therapies and position Abu Dhabi as a global hub for life sciences and precision medicine. Leverages insights from the Emirati Genome Programme.
• Regeneron PharmaceuticalsflagshipStrategic or Co-development Partner · 25 April 2024Collaboration to develop in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Mammoth receives $100M total upfront ($95M equity + $5M upfront payment) and is eligible for up to $370M per target in development, regulatory and commercial milestones plus royalty rates from single digits to mid-teens. Regeneron obtains broad access to Mammoth's editing technologies for 5.5 years with option to extend. Regeneron leads development and commercialization.
• BayercoreStrategic or Co-development Partner · 9 January 2022Collaboration focused on liver disease using Mammoth's ultra-small CRISPR technology. Mammoth received $40M upfront payment. Bayer collaboration connects with their growing cell and gene therapy business.
• Vertex PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2021Collaboration to develop in vivo gene-editing therapies for serious diseases. Two in vivo indications. Mammoth received $40M upfront payment and investment, with potential for up to $650M in future payments plus tiered royalties on net sales. Vertex brings complementary AAV delivery technology via Affinia and track record in complex diseases.
• GSK Consumer HealthcareminorStrategic or Co-development PartnerCollaboration to develop COVID-19 test using CRISPR-based platform.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage CRISPR gene editing company developing Cas9-based ex vivo and in vivo therapies, including Casgevy (the first FDA-approved CRISPR therapy). It directly competes with Mammoth in the gene editing therapeutic space and shares the same B2B pharma partnership model, though it relies on legacy Cas9 rather than ultracompact nucleases.
• Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR therapeutics company with leading programs in transthyretin amyloidosis and hereditary angioedema using Cas9 delivered via LNP. It is a direct competitor to Mammoth's in vivo editing strategy and has demonstrated clinical proof-of-concept that Mammoth still needs to achieve.
• Editas Medicine: Editas Medicine develops CRISPR-based gene editing therapies using both Cas9 and Cas12a nucleases for rare diseases including sickle cell disease and inherited retinal diseases. It directly competes with Mammoth in the gene editing platform space and pursues a similar partner-enabled commercialization strategy.
• Beam Therapeutics: Beam Therapeutics is a clinical-stage company pioneering base editing, one of the same editing modalities Mammoth offers. It is a direct competitor in the precision gene editing field and shares Mammoth's B2B pharma partnership model, including a high-profile partnership with Verve Therapeutics.
• Verve Therapeutics: Verve Therapeutics develops in vivo base editing therapies for cardiovascular disease, including an APOC3-targeting program that directly overlaps with Mammoth's MB-111 lead indication. Verve is a leading direct competitor in the in vivo gene editing space for dyslipidemias and cardiovascular indications.
• Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies using its Cas12a chRDNA platform. It shares Mammoth's heritage in novel Cas protein research and competes in the broader CRISPR platform space, though its focus is ex vivo cell therapy rather than in vivo editing.
• Sherlock Biosciences: Sherlock Biosciences is a CRISPR-based molecular diagnostics company that developed the SHERLOCK platform, a direct competitor to Mammoth's DETECTR platform. Both companies spun out of CRISPR pioneer labs (Doudna and Zhang respectively) and compete in CRISPR-based nucleic acid detection for infectious disease and oncology diagnostics.
• Prime Medicine: Prime Medicine develops prime editing therapies, a precision gene editing modality that overlaps with Mammoth's RT editing and base editing platforms. It is a direct competitor in next-generation gene editing modalities and shares Mammoth's strategic partnership approach with major pharma.
• Arbor Biotechnologies: Arbor Biotechnologies is a gene editing company that discovered novel Cas proteins through metagenomic mining, directly mirroring Mammoth's AI-enabled protein discovery approach. It pursues both therapeutic in vivo editing and ex vivo cell therapy, making it a closely comparable platform peer.

Others

• Synthego: Synthego is a genome engineering tools company providing synthetic CRISPR guides and cell engineering services. It is a technology supplier to Mammoth (providing modified guides for ex vivo sickle cell therapy research) and an enabling ecosystem participant in the broader CRISPR tools and reagents market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/mammothbiosci
• LinkedInlinkedin.com/company/mammothbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mammoth Biosciences